Lindahl advises Medivir in directed share issue of SEK 45 million

Through the directed share issue, Medivir raises SEK 45 million before issue costs. The capital enables the clinical development of the drug candidate MIV-711 for the treatment of Osteogenesis Imperfecta (congenital brittle bone disease), a new and strategically important indication for Medivir. In November 2025, MIV-711 was granted Orphan Drug Designation by the US Food and Drug Administration (FDA), which provides important advantages such as market exclusivity and reduced development costs.

The subscription price in the directed share issue amounted to SEK 0.50 per share, representing a premium of 19 per cent to the closing price on 5 February 2026. The board of directors considers the issue to be a time- and cost-efficient means of raising additional capital for the company, and that Carl Bennet AB, as a financially strong and long-term shareholder, strengthens Medivir's position in negotiations regarding future partnerships and out-licensing.

Lindahl's team consisted of Erika Svensson and Theo Biström.

About our client Medivir

Medivir AB (publ) is a pharmaceutical company focused on developing innovative treatments for diseases with significant unmet medical needs. The company targets indication areas where available treatment options are limited or non-existent and where there are substantial opportunities to offer meaningful improvements for patients. Medivir's share is listed on Nasdaq Stockholm, Small Cap.

Read more in Medivir's press release here.